
    
      Patients will be offered to participated in the study when they start TB treatment. All the
      enrolled patients will immediately be switched to rifabutin and randomized, to one of the RBT
      doses that will be then adapted to the allocated RBT regimen according to a cross over
      scheme. Three full pharmacokinetics profile will be performed at different time point :
      before initiation of ARV, after three weeks of the first RBT dosage and after three weeks of
      the secondRBT dosage. Patients will then be referred to the national program for further
      treatment. A follow-up visit will be planned at the end of the antiTB treatment.
    
  